EnglishThe viral infectivity factor (Vif) is an essential component of the HIV-1 infectious cycle. Vif counteracts the action of the cytidine deaminase APOBEC3G (AP3G), which confers nonimmune antiviral defense against HIV-1 to T lymphocytes. Disabling or interfering with the function of Vif could represent an alternative therapeutic approach to AIDS. We have expressed a natural mutant of Vif, F12-Vif, in a VSV-G-pseudotyped lentiviral vector under the Tat-inducible control of the HIV-1 LTR. Conditional expression of F12-Vif prevents replication and spreading of both CXCR4 and CCR5 strains of HIV-1 in human primary T lymphocyte and T cell lines. T cells transduced with F12-Vif release few HIV-1 virions and with reduced infectivity. Several lines of evidence indicate that HIV-1 interference requires the presence of both wild-type and F12-Vif proteins, suggesting a dominant-negative feature of the F12-Vif mutant. Surprisingly, however, the F12-Vif-mediated inhibition does not depend on the reestablishment of the AP3G function.
| Data di pubblicazione: | 2005 |
| Titolo: | T Lymphocytes transduced with a lentiviral vector expressing F12-Vif are protected from HIV-1 infection in an APOBEC3G-independent manner |
| Autore/i: | Vallanti G.; Lupo R.; Federico M.; Mavilio F.; Bovolenta C. |
| Autore/i UNIMORE: | |
| Rivista: | |
| Volume: | 12 |
| Pagina iniziale: | 697 |
| Pagina finale: | 706 |
| Codice identificativo ISI: | WOS:000232327300015 |
| Codice identificativo Scopus: | 2-s2.0-25144493560 |
| Citazione: | T Lymphocytes transduced with a lentiviral vector expressing F12-Vif are protected from HIV-1 infection in an APOBEC3G-independent manner / Vallanti G.; Lupo R.; Federico M.; Mavilio F.; Bovolenta C.. - In: MOLECULAR THERAPY. - ISSN 1525-0016. - STAMPA. - 12(2005), pp. 697-706. |
| Tipologia | Articolo su rivista |
File in questo prodotto:
http://hdl.handle.net/11380/640436
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
Copyright © 2019